Moderna, Inc. (MRNA) stock experienced a significant pre-market decline of 5.1% following an analyst price target revision. The pre-market plunge occurred on Thursday, March 6th, 2025.
According to reports, Berenberg analysts adjusted their price target for Moderna down to $30 from the previous target of $33. The analysts maintained their "Hold" rating on the stock, reflecting a cautious outlook.
The downward revision of the price target by Berenberg analysts appears to have contributed to the pre-market sell-off in Moderna's shares. Investors reacted negatively to the reduced price expectations, as reflected in the stock's 5.1% drop during the pre-market trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.